Parallel Health has introduced a new technology designed to map the metabolic activity of the skin microbiome, aiming to advance precision approaches to skin aging, according to the company. The platform, called Metabolic Microbiome Profiling, identifies the bioactive compounds that skin microbes are actively producing or failing to produce, addressing a longstanding limitation in microbiome science that has focused primarily on identifying microbial species rather than their function.
According to the company, the technology analyzes outputs such as vitamins, antioxidants, peptides, lipids and short chain fatty acids that influence skin health, including barrier integrity, immune response and visible aging. It builds on the company’s prior use of quantitative whole genome sequencing to measure microbial abundance at the strain level, adding a functional layer that links microbial presence to biological activity.
The company claims that understanding microbial metabolism is critical because the same species can produce beneficial or harmful effects depending on individual conditions. Beneficial metabolites may support collagen production, hydration and skin barrier function, while harmful byproducts can contribute to inflammation, oxidative stress and signs of aging.
Parallel Health said it translates these insights into personalized treatment protocols through its telehealth dermatology platform, combining diagnostics with targeted interventions. The company positions the technology as part of a broader shift toward precision health, applying data driven approaches to skin care and longevity.
The company develops microbiome based dermatology solutions spanning diagnostics, custom formulations and therapeutic pipelines, with a focus on individualized treatment strategies for skin conditions and aging.
